Indication
Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
Loading your page…
Loading your page…
Melanoma
Marketing Authorisation Holder: Amgen Europe B.V.
EMA Authorisation: 16/12/2015
INN: talimogene laherparepvec
AI Drug & Interaction Analysis
Free account required
Ask Osler about Imlygic: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.